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Abstract The aim of this study is to determine the prognostic
value of tumor markers, as squamous cell carcinoma antigen
(SCCAg) and cytokeratin-19 fragment (CYFRA 21.1) and
interleukin 6 (IL-6), vascular endothelial growth factor
(VEGF), soluble tumor necrosis factor receptor I (sTNF RI),
and sTNF RII in patients with squamous cell carcinoma of the
cervix. The subjects of analysis were 138 patients with stage
I–IVA according to the International Federation of
Gynecology and Obstetrics (FIGO) classification. The collect-
ed research material comes from one oncology center. During
the 10 years of follow-up, 56 relapses and 53 deaths were
observed, and recurrent disease in early stage was confirmed
in 45 % of patients. The pretreatment serum levels of SCCAg
and CYFRA 21.1, and cytokines IL-6, VEGF, sTNF RI, and
sTNF RII were determined in all patients. The probability of
disease-free survival (DFS) and overall survival (OS) was
evaluated using the log-rank test and the Cox regression mod-
el. Based on the ROC curve analysis for patients with recur-
rence, the largest area under the curve was demonstrated for
SCCAg and IL-6 and for patients who died, for SCCAg and
VEGF. Cox analysis demonstrated that independent
prognostic factor for DFS was only SCCAg and for OS cyto-
kine IL-6 and SCCAg, but in patients with early stage the
prognostic value for DFS was VEGF, whereas IL-6 and
CYFRA 21.1 for OS. Serum level of VEGF, CYFRA 21.1
and IL-6 before treatment in patients with early stage cervical
cancer appears to be an important prognostic factor.
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Introduction
Due to well-developed screening programs, the incidence of
cervical cancer, especially squamous cell carcinoma (SCC),
has decreased dramatically, although cervical cancer is still
the third most diagnosed cancer and the fourth highest cause
of death among females around the world [1].
Some pathologic features, such as tumor diameter, lymph
node involvement, lymph vascular space invasion, extend of
the tumor, and depth of stromal invasion, have been proven as
clinically important [2]. Optimal management consists of ap-
propriate treatment methods after the precise staging, follow-
ing detection as early as possible, and the best salvage therapy.
Early detection of recurrence, especially at the early stages in
cervical cancer patients, is of main importance. The survival
improvement from early detection of disease relapse has been
found [3, 4]. So far, several methods are available for recur-
rence detection, but the disease is usually advanced with the
accompanying clinical symptoms. The main problem is detec-
tion of the disease in the preclinical phase, with no visible
lesions in computed tomography (CT) or magnetic resonance
(MRI), while the chance for a cure is the highest. Several
tumor markers have been investigated so far, in which the
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most commonly used is squamous cell carcinoma antigen
(SCCAg). In studies presented by Scambia et al. and
Strausss et al., 74–88 % of patients presented an elevation of
SCCAg with association of disease, while 70–86 % of re-
curred patients were proven to have elevated SCCAg [5, 6].
In some cases, SCCAg is not elevated in disease recurrence or
at the initial diagnosis [5]. Investigation of the most sensitive
useful marker to detect disease recurrence at the earliest stage
is needed.
One of the most promising appears to be serum cytokines
produced by a wide variety of cells, mainly monocytes and
macrophages, which plays a central role in the regulation of
the inflammatory and immune system [7]. The correlation of
cytokines with disease severity and survival has been studied
to date in breast cancer, ovarian cancer, as well as cervical
cancer [8–13].
The aim of the study was to determine the prognostic value
of pretreatment serum levels of the cytokines interleukin 6
(IL-6), vascular endothelial growth factor (VEGF), soluble
tumor necrosis factor receptor (sTNF RI) and sTNF RII in
patients with SCC of the cervix and the tumor markers
SCCAg and cytokeratin-19 fragment (CYFRA 21.1).
Materials and test methods
During the period from 2005 to 2008, 138 cervical cancer
patients (ages 26–85; median 54 years) with stage I–IVA,
according to the International Federation of Gynecology and
Obstetrics (FIGO) classification, were treated at the Maria
Sklodowska-Curie Memorial Cancer Centre and Institute of
Oncology in Warsaw. Written informed consent from all pa-
tients and the approval of the local Ethical Committee Nr 26/
2005 was obtained before treatment. The workup for all pa-
tients performed before treatment included clinical examina-
tion, computed tomography (CT) or magnetic resonance im-
aging (MRI), chest X-ray, blood count, and biochemistry. The
pretreatment serum levels of the tumor markers SCCAg and
CYFRA 21.1, and certain cytokines, such as IL-6, VEGF,
sTNF RI, and sTNF RII, was determined for all patients.
SCCAg was determined by chemiluminescence (CMEIA)
from Architect i2000sr kits, Abbott Diagnostics, CYFRA 21.1
was determined by electrochemiluminescence using Cobas sys-
tem 6000 sets from Roche, and cytokine concentrations were
determined in serum using ELISA kits from R&D Systems.
Clinicopathological features of patients with squamous cell
carcinoma of the cervix, taking into account the clinical con-
dition, are presented in Table 1. In patients treated surgically,
the assessment of lymph nodes was performed during the
histological assessment of the surgical specimen. In patients
treated with radiochemotherapy (CCR), the assessment of
lymph nodes was performed using the imaging studies as
MRI or CT. Twenty-nine patients (20.9 %) underwent the
surgical treatment. Among this group, nine (6.5 %) patients
were treated with radical hysterectomy (RH) with no treat-
ment afterwards, ten (7.2 %) with RH and brachytherapy
(BT), and ten (7.2 %) with RH and CCR. 109 (79.1 %) were
treated with CCR alone. The SC type of the tumor was con-
firmed histologically for all patients before treatment. CCR
consisted of irradiation with high megavoltage photons,
15 MeV X-rays, from a linear accelerator, and chemotherapy.
External beam radiotherapy (EBRT) was administered in daily
fractions of 1.8–2 Gy up to 45–50 Gy. Concomitant chemo-
therapy (CHT) consisted of once-weekly infusion of cisplatin
(40 mg/m2 dose) with appropriate hydration. During the first
2 years, patients were followed every 3 months and twice per
year thereafter. In cases of suspicion of recurrence, biopsies
based on CT or MRI were obtained. In patients with SCC of
the cervix, the pretreatment serum levels of cytokines and
tumor markers were determined in relation to the clinical con-
dition, and assessed after approximately 10 years of follow-
up.
The reference group consisted of 50 healthy people in our
earlier study, designated as cutoff value for the cytokines IL-6,
VEGF, sTNFRI, sTNFRII, assuming the 95th percentile (14).
For statistical calculations, Statistica PL 6.0 for Windows and
Excel 7.0 for Windows were used. For the comparison of two
independent groups, a nonparametric U test, the Mann-
Whitney test, was adopted. The probability of disease-free
time (DFS) and overall survival (OS) was evaluated with uni-
variate analysis using the log-rank test and the Cox regression
model. The cutoff level of significance was set at P<0.05. The
analysis of the diagnostic power of determined parameters
was made using the MedCalc statistical program, which in-
cluded the determination of the areas under the receiver oper-
ating characteristics (ROC) curves (AUC), interdependencies
AUC of determined parameters, and the determination of cut-
off points for the studied biomarkers, with the optimal sensi-
tivity and specificity of the tests.
Results
Clinical observation of the analyzed patients was conducted
until the end of 2013. During approximately 10 years of
follow-up (median, 1572 days; range, 102–3375), disease re-
lapse was observed in 56 patients (41 %), and there were 58
(42 %) deaths, including 5 deaths not related to the disease.
The median time to relapse was 375 days.
In 82 patients with no recurrence confirmed clinically, the
majority of determined parameters levels were elevated in
50 % of patients, with the exception of CYFRA 21.1 and the
soluble receptor sTNFR II, while their median concentrations
(with the exception of IL-6 and sTNF RI) were below the
accepted cutoff points.
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In the group of 56 patients with confirmed recurrence, the
percentages of elevated concentrations and the median of all
biomarkers determined were significantly higher, with the most
frequently observed elevated levels from sTNF RI (96 %),
SCCAg, and IL-6 (84%). TheMann-Whitney test demonstrated
that, in patients for whom recurrence of the disease was con-
firmed, the concentrations of all the examined parameters before
treatment were significantly higher compared to the levels in
patients in remission (Table 2).
Based on the ROC curve analysis carried out in re-
lapsed patients versus patients in remission, the largest
area under the curve (AUC) was demonstrated for
SCCAg (0.833) and IL-6 (0.799). For other determined
biomarkers, AUCs were CYFRA 21.1, 0.763; VEGF,
0.711; sTNF RI, 0.701; and sTNF RII, 0.682 (Fig. 1).
No significant differences were found between the fields
under the ROC curves for any of the parameters
studied.
Table 1 Clinicopathological features of patients with squamous cell carcinoma of the cervix, taking into account the clinical condition
Characteristics Patients, n=138 Patients with no recurrence, n=82 Patients with relapse, n=56 Deaths, n=53
N % N % N % N %
Median age (range, years) 54 (26–85) 54 (28–84) 54 (26–85) 54 (26–85)
Menopausal status
Premenopausal 47 34 28 34 19 34 20 34
Postmenopausal 91 66 54 66 37 66 38 66
FIGO stage
I 38 28 34 41 4 7 4 7
II 40 29 22 27 18 32 16 30
III 57 41 26 31 31 55 31 58
IV 3 2 0 0 3 5 2 4
Histological grade/G/
G1 8 6 7 11 1 2 1 2
G2 61 44 41 63 20 47 18 34
G3 39 28 16 25 22 51 21 40
Gx 30 22 17 21 13 23 13 25
Lymph node status
Negative 105 78 67 83 38 70 33 62
Positive 30 22 14 17 16 29 18 34
Not evaluable 3 2 1 1 2 4 2 4
Median SCCAg (ng/mL) 2.9 1.6 6.7 6.2
N number, FIGO International Federation of Gynecology and Obstetrics, SCCAg squamous cell carcinoma antigen
Table 2 Median value, concentration ranges, and the percentage of patients with elevated levels of tumor markers and cytokines, and significant
differences depending on the clinical condition
Markers/ Cytokines Patients with remission, n=82 Patients with recurrence, n=56 Remission vs. recurrence
Median range % Median range % P value
SCC Ag (ng/mL) 1.6 (0.2–54.6) 50 6.6 (0.2–299) 84 0.001
CYFRA 21.1 (ng/mL) 1.85 (0.3–105.7) 26 3.5 (0.5–62) 52 0.001
IL-6 (pg/mL) 2.6 (0.7–237) 54 5.5 (0.7–119.5) 84 0.001
VEGF (pg/mL) 325 (51.5–1401) 50 396 (99–2000) 63 0.045
sTNF RI (pg/mL) 1525 (815–2600 72 2140 (1015–5000) 96 0.001
sTNF RII (pg/mL) 2492 (1577–5000) 23 2817 (1155–5000) 60 0.006
SCCAg squamous cell carcinoma antigen, CYFRA 21.1 cytokeratin fragment detected by antibodies BM 19–21 and KS 19, IL-6 interleukin 6, VEGF
vascular endothelial grown factor, sTNFRI soluble tumor necrosis factors receptor I, sTNFRII soluble tumor necrosis factors receptor II
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In the group of 53 patients who died, the percentages of
elevated concentrations of the studied parameters and their me-
dians were similar to those in patients who relapsed. In patients
whose observation ended in death, the most clinical utility was
demonstrated for SCCAg (AUC=0.811), VEGF (AUC=
0.783), and IL-6 (AUC=0.754). For the other parameters,
AUCs were CYFRA 21.1, 0.706; sTNF RI, 0.644; and sTNF
RII, 0.634 (Fig. 2). In the ROC curve analysis also, significant
differences between the AUC for SCCAg and sTNF RI
(P<0.044), and SCCAg and sTNF RII (P<0.039) were con-
firmed. Furthermore, theMann-Whitney test demonstrated that,
in these patients, the designated concentration of all tumor
markers and cytokines were significantly higher (P<0.01) com-
pared with their concentration in patients who were still alive.
Then, evaluation of the dependence between the concen-
trations of determined parameters before treatment and the
DFS and OS was performed. Based on the ROC curve analy-
sis for the determined biomarkers, the other cut-points were
set, while maintaining optimal sensitivity and specificity of
the test for groups with recurrence versus no recurrence and
death versus being alive (Table 3). Relapse was observed even
in patients with early disease, i.e., 11 % (4/38) in patients in
FIGO stage I and 45 % (18/40) in FIGO II, and in the ad-
vanced stages, 54 % (31/57) in FIGO III and in all patients in
stage IV. Relapse occurred in the highest proportion of pa-
tients with histological grade G3, 56 % (22/39). With G2
and G1, it was in 33 % (20/61) and 13 % (1/8), respectively.
Among patients for whom regional lymph nodes were
assessed as free, recurrence was observed in 36 % (38/105),
while for patients with positive nodes, recurrence was ob-
served in 53 % (16/30).
Because FIGO stage II recurrent disease was confirmed
in 45 % of patients, the survival analysis in this group was
performed. The log-rank test demonstrated a correlation be-
tween VEGF and the age of the patients with DFS, while
multivariate Cox analysis found that only VEGF is an inde-
pendent prognostic factor in patients in stage FIGO II
(P<0.016 (HR 3.559; 95 % CI 2.526–4.592). Assessing
the relationship between the concentrations of the deter-
mined parameters before treatment in the entire study group
and DFS in univariate analysis and the log-rank test, in
addition to the FIGO stage, histological grade (G), and
lymph node status, confirmed the relationship between the
concentration of the tumor markers SCCAg and CYFRA
21.1, and the assayed cytokines and their receptors IL-6,
VEGF, sTNFR I, sTNF RII, and DFS. However, in a Cox
multivariate analysis, the prognostic value for DFS was con-
firmed for the FIGO stage, P<0.023 (HR 1.620; 95 % CI
1.204–2.035), and G, P<0.031 (HR 2.195; 95 % CI 1.485–
2.905). Among the studied parameters the statistically sig-
nificant influence on DFS was ascertained for SCCAg,
P<0.012 (HR 2.649; 95 % CI 1.890–3.408) (Fig. 3).
Of the 138 patients enrolled in the study, after approximate-
ly 10 years of follow-up, 53 died from cancer, including 50
patients with confirmation of earlier disease recurrence. The
median follow-up time from recurrence to death in this group
was 234 days. Patients in the early stages (FIGO I-II)
accounted for 36 %. Univariate analysis carried out in these
patients showed a significant relationship between the concen-
trations of SCCAg (P<0.005), CYFRA 21.1 (P<0.011), IL-6
(P<0.0001), VEGF (P<0.004), and OS. For these parameters,
the prognostic value for OS of the patients in the early stages
was confirmed in the Cox analysis for concentrations of IL-6,
P<0.003 (HR 6.449; 95 % CI 5.212–7.686), and CYFRA
21.1, P<0.009 (HR 5.192; 95 % CI 3.959–6.425). Assessing
the prognostic value of tumor markers and cytokines in the
entire study group log-rank test showed a significant relation-
ship between the concentrations of all biomarkers and OS.
However, in the multivariate Cox analysis, the prognostic val-
ue for OS of patients with SCC of the cervix was confirmed
only for concentrations of SCCAg, P<0.027 (HR 2.512; 95%














Fig. 1 Receiver operating characteristic curves for SCCAg, CYFRA
21.1, and cytokines in cervical cancer patients with recurrence














Fig. 2 Receiver operating characteristic curves for SCCAg, CYFRA
21.1, and cytokines in cervical cancer patients who had died
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CI 1.697–3.327), and IL-6, P<0.003 (HR 3.768; 95 % CI
2.892–4.644) (Fig. 4).
Discussion
Cervical cancer is a malignancy of the reproductive tract de-
rived from a variety of cell types. Cancer derived from squa-
mous cells occurs more frequently and has a lower aggressive-
ness; however, it happens that, despite the early stage of the
disease, recurrences are observed.
Therefore, looking for factors that at the time of diagnosis
would be helpful in predicting its course and thus the selection
of the optimal treatment regimen is of main importance. In the
presented studies, the possibility of using concentrations of
standard tumor markers for SCC measured before treatment
was evaluated. Tumor markers SCCAg and CYFRA 21.1,
cytokines IL-6 and VEGF, and soluble tumor necrosis factor
receptors sTNFR I and II were evaluated as possible prognos-
tic factors in all patients in the early stages of cancer develop-
ment with a similar prognosis. Within the group of patients
who, during a 10-year period of observation, have had recur-
rence of the disease, concentrations of all markers were sig-
nificantly higher compared to concentrations noted in patients
who were in remission. Furthermore, in cases of patients with
progression, the highest diagnostic sensitivity was noted for
concentrations of SCCAg and IL-6. In the group of patients
who died, the highest diagnostic sensitivity was noted for
VEGF, as well as SCCAg and IL-6. Hoogendam et al. evalu-
ated the utility of various biomarkers in the detection of cer-
vical cancer. They proved that SCCAg and high-sensitivity C-
reactive protein (hsCRP) have the highest diagnostic sensitiv-
ity. In the cases of VEGF and IL-6, similar results were not
confirmed [13]. In the next step of our studies, we determined
the cutoff points for all parameters based on the ROC curve,
while maintaining the optimum sensitivity and specificity of
the tests. From this, we conducted an analysis of patient
Table 3 Tumor marker and cytokine test characteristics for remission or recurrence for cervical cancer patients alive or have died
Markers/cytokines Patients remission/recurrent Patients alive/died
Cutoff Sensitivity Specificity P value Cutoff Sensitivity Specificity P value
SCCAg (ng/mL) 1.8 82.1 54.9 0.001 1.6 81.0 50.0 0.001
CYFRA 21.1 (ng/mL) 2.6 65.2 68.2 0.001 3.5 51.1 80.0 0.001
IL-6 (pg/mL) 3.4 83.7 63.3 0.001 3.4 83.0 65.3 0.001
VEGF (pg/mL) 352 60.4 61.1 0.037 352 62.8 63.8 0.007
sTNF RI (pg/mL) 1540 81.8 55.3 0.001 2095 51.6 83.7 0.004
sTNF RII (pg/mL) 3500 55.0 85.7 0.002 2984 65.0 68.6 0.019
SCCAg squamous cell carcinoma antigen, CYFRA 21.1 cytokeratin fragment detected by antibodies BM 19–21 and KS 19, IL-6 interleukin 6, VEGF
vascular endothelial grown factor, sTNFRI soluble tumor necrosis factors receptor I, sTNFRII soluble tumor necrosis factors receptor II


































































Fig. 3 Disease free survival and VEGF concentrations in FIGO stage II and SCCAg concentrations in the entire group of patients
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survival rate, searching for prognostic factors for both DFS
and OS. Similar studies have been carried out by other au-
thors, who analyzed the optimum cutoff points for biomarkers
determined before beginning treatment, taking into consider-
ation the patients’ clinical condition. Adopting individual cut-
off points based on the ROC curve is important because it can
increase sensitivity. This approach, in turn, may increase the
chance of detecting precancerous states and enable earlier de-
tection of recurrence [13–17].
As is known, the classic and widely recognized prognostic
factor in patients with malignancy is the degree of develop-
ment. Similar to our research, other authors have observed that
the risk of recurrence of cervical carcinoma depends on the
disease stage. Recurrence of the cancer is observed quite of-
ten. The consequences of the process are deaths [13, 15].
However, in our studied group, recurrence had already been
observed in 45% of patients in FIGO II stage. Because of this,
we searched for additional prognostic factors in this specific
group of patients.
The research proved that increased concentration of the
proangiogenic cytokine VEGF is an independent, and at the
same time poor, prognostic factor for DFS In patients in
stage II cancer development. VEGF plays a specific role in
the process of neoangiogenesis, which is in the progression
of the disease and metastasis. The role of angiogenesis in the
progression of cancer is very well documented [18–22].
Researchers found that VEGF concentrations are connected
with clinical stage and size of the tumor, as well as their
usefulness in monitoring the course of disease [19, 23].
Zustrzeel et al. stated that marking VEGF pretreatment con-
centrations in cervical cancer patients can be useful in deter-
mining DFS and OS. The dependence of VEGF on DFS and
OS was confirmed in multivariate analysis using the Cox
model. However, the results of the analysis concerned the
entire studied group, which included adenocarcinoma and
adenosquamous patients [14]. Although other authors have
confirmed the participation of VEGF in the progression of
cervical cancer, they did not indicate its predictive value
[24]. Our studies have demonstrated the prognostic value
of VEGF for DFS in patients with FIGO stage II SCC.
Therefore, it appears that the relationship we have
established between VEGF concentrations and DFS in pa-
tients in FIGO stage II may prove to be useful in clinical
practice.





















































































































FIGO I-II FIGO I-II
Fig. 4 The relationship between overall survival, CYFRA 21.1, and IL-6 in FIGO stages I-II, SCCAg and IL-6 in the entire group of patients
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A similar analysis of OS in the first stage was conducted in
patients in stage FIGO I+II. The analysis demonstrated the
important role of proinflammatory cytokines IL-6 and
CYFRA 21.1 as independent prognostic factors. IL-6 is a
pleiotropic cytokine produced by various cells, mainly mono-
cytes and macrophages. It plays a key role in the regulation of
inflammation and immune responses, and in the pathogenesis
and progression of cancer [8, 12, 25, 26].
Earlier studies have shown that IL-6 concentrations in-
crease with the development of clinical stages in patients with
cervical cancer. Complimentary marking of IL-6with the stan-
dard tumor marker SCCAg, especially for patients in the early
stages of clinical development, increases its diagnostic sensi-
tivity [25]. In recent years, authors say that marking IL-6
concentrations before treatment can influence the estimation
of DFS and OS. They place stress on the important role of
proinflammatory cytokines, IL-6 included, in the progression
of cervical cancer, particularly in early stages of development
[5, 27]. Our studies confirmed those reports. Furthermore, the
studies showed the important role of IL-6 on DFS and OS, not
only for patients in FIGO stages I-II, but for the entire studied
group (FIGO I-IV). Other researchers have not demonstrated
such dependence when analyzing a comparable group.
However, their observation period was considerably shorter
[28].
CYFRA 21.1 is a cytokeratin-19 fragment that is soluble in
serum. Elevated concentrations of this marker were found in a
large percentage of SCC patients with different localizations
of the tumor [25, 29, 30]. In cervical cancer patients, concen-
trations of CYFRA 21.1 increase with the progression of the
disease. The literature emphasizes that this marker has a lower
diagnostic utility compared to the value of SCCAg, suggest-
ing complimentary utility of marking CYFRA 21.1 with
SCCAg and other biomarkers [31, 32]. Some authors claim
that, in patients in the early stages of cancer development,
determining CYFRA 21.1 before beginning treatment might
have prognostic value [28, 33]. Our studies have confirmed
that CYFRA 21.1 has a prognostic value in connection to OS
in patients with stage FIGO I-II.
In the presented study, a shorter period of survival
was observed in patients with recurrence and elevated
SCCAg concentrations when compared to patients with
recurrence having normal SCCAg concentrations. Like
other authors, we have confirmed the prognostic value
of the standard SCCAg marker for both DFS and OS.
This is true for the whole of the studied group irrespec-
tive of the patients’ FIGO stage [15, 16, 34]. Although
the results of our study and the results presented in the
works of other authors demonstrate the important prog-
nostic value of SCCAg in the early stages of cancer
development, researchers attempt marking SCCAg with
other biomarkers, which is important in cases where the
marker is not elevated [13, 34–36].
The assessment of the correlation of tumor markers with
the response to any treatment might be also interesting, but
due to relatively small number of patients in each treatment
group we did not perform such analysis. The limitations in our
study are the heterogeneous study population, relatively small
sample size, but this is the single institution experience.
In conclusion, our study illustrated that elevated VEGF and
CYFRA 21.1 concentrations before beginning treatment in
patients with SCC of the cervix at the earlier stages of clinical
development can be poor prognostic factors. Moreover, we
demonstrated that in patients with SCCAg concentration
levels that are not increased before beginning treatment, mea-
suring interleukin 6 may be helpful in the prognosis of the
disease.
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